Tuberculousmeningitis: what is the best treatment regimen?

Size: px
Start display at page:

Download "Tuberculousmeningitis: what is the best treatment regimen?"

Transcription

1 Tuberculousmeningitis: what is the best treatment regimen? H S Schaaf Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University

2 Introduction TBM is the most serious complication of TB causing considerable morbidity and mortality even if treated with anti-tb drugs Outcome depends on the stage of TBM at the point of diagnosis, but even patients with early disease stage may deteriorate Rate of TBM is approximately 1:40 cases majority in young children <3 years of age Associated mainly with primary infection, but in some cases occur years after primary infection TBM is the most common bacterial meningitis in the Western Cape, and most likely, in South Africa

3 CT MRI Scans Courtesy Ronald van Toorn

4 Pathogenesis of TBM Haematogenous disseminationof bacilli from the primary complex establishes a cortical or meningeal focus. This focus soon (or later in some cases) proceeds to caseate and discharge its contents into the subarachnoid space. In some cases haematogenous dissemination may establish a caseatingfocus in the choroid plexus or in the walls of the ventricles from which TBM may develop. In a few cases a caseousprocess extends from adjacent structures (e.g. vertebrae or middle ear) to involve the CNS. Donald et al; Journal of Infection (2005) 50,

5 Axial T1 gadolinium T1 MRI demonstrating miliarynodules in the quadrigeminal cistern.

6 MRI T2 black = Tuberculoma Scans courtesy Ronald van Toorn

7 The Chemotherapy of Tuberculous Meningitis Before chemotherapy TBM was universally deadly The mean time from diagnosis to death in pretreatment era was 19 days (Lincoln EM. Tuberculousmeningitis i9n children. Am Rev Tuberc1947; 56: ) There is no place for a wait and see attitude to diagnosis a medical emergency.

8 Components of TBM treatment Three major components: - Anti-TB chemotherapy -Management of raised intracranial therapy due to obstructive hydrocephalus (communicating vs. noncommunicating; medical vs. surgical) -Modulation of the destructive elements of the immune response, most important of which is the vasculitis Today only discuss anti-tb treatment Donald PR. The chemotherapy of TBM in children and adults. Tuerculosis 2010;90:375-92

9 Main objectives in TB Rx To rapidly kill most bacilli in order to: - prevent disease progression - prevent transmission of infection - prevent development of drug-resistance To effect cure and prevent relapse (eliminate dormant bacilli) To do the above with minimal adverse events In CNS TB drugs need to cross the blood brain barrier

10 1 st -line Anti-TB agents CSF penetration Anti-TB drug CSF Suggested dose Suggested dose penetration (children) (adults) Isoniazid Good 15 mg/kg Up to 500 mg Rifampicin Moderate to Poor 20 mg/kg Up to 1000 mg Pyrazinamide Good 40 mg/kg Up to 2000 mg Ethambutol Poor (±20% acute phase) Streptomycin Poor (±20% acute phase) If used 25 mg/kg Not recommended Up to 2500 mg Up to 1000 mg

11 2 nd -line Anti-TB agents CSF penetration Anti-TB drug CNS Suggested dose penetration (children) Ethionamide Good (>80%) 20 mg/kg FQNs Moderate to - Levofloxacin Good 20 mg/kg - Moxifloxacin (50-60%) mg/kg (no evidence) Suggested dose (adults) mg 1000 mg 400 mg (800? QT problems?) Terizidone/Cs Good mg/kg mg 2 nd -line Inject Poor (<20%) 20 mg/kg Up to 1000 mg PAS Poor (20%) 200 mg/kg Up to 12 g daily Linezolid Good 10 mg/kg bd Up to 600 mg bd Clofazimine Poor 3-5 mg/kg 100 mg

12 Best Drugs for treatment of TBM»INH»Fluoroquinolones»PZA»RMP»ETH»Cycloserine/terizidone»Newer drugs Linezolid

13 Woodfield J, Argent A. J Trop Pediatr 2008;54:220-4

14 It is of interest that this review found no evidence that the introduction of RMP has had a significant effect on the mortality of TBM in adults, whereas mortality in children has declined significantly. As a relatively high-dosage of RMP will often be used in childrenthis may have contributed to the much improved outcome in children.

15 Intensified treatment did not result in increased toxicity. 6 month mortality was substantially lower in (adult) patients given high-dose rifampicin intravenously (ten [35%] vs20 [65%]), which could not be explained by HIV status or severity of disease at the time of presentation (adjusted HR 0 42; 95% CI ; p=0 03). Published online October 25, 2012

16 Ellardet al. Am Rev RespirDis 1993; 148: INH in CSF: at the dosages generally used (about 8-10 mg/kg, (as in this study) the drug exposures achieved in the CSF are similar to those attained in the serum (and by implication in the lungs) with the doses normally employed (5 to 6 mg/kg) for treatment of pulmonary tuberculosis.

17 Recent experience DS-TBM in children Study in Western Cape: 6HRZEth (HIV-uninfected) and 9HRZEth (HIV-infected) with strict home-based care in selected cases or hospitalised care for full duration of Rx 184 children TBM stage I 12%, St II 53%, St III 35% In 23 (12.5%) cases Rx was prolonged to 7-15 months. Reasons were: Hepatic toxicity (raised ALT only) 8; Rx interruption 3; TB brain abscesses 6; INH-monoresistance 2; and TB-IRIS -4 Outcome at end of Rx: -Normal 43%; Mild sequelae 37%; Severe sequelae 16% and Death in 4%. Van ToornR, Schaaf HS, et al. PIDJ in press

18 What should we consider when deciding on a TBM treatment regimen? No RCT (some by Thwaites) on TBM treatment, very little information on relapse of TBM and few options as far as drugs are concerned Stage of TBM: early diagnosis (stage 1 or early stage 2) much better prognosis than late stage 2 or stage 3 irrespective of available anti-tb drugs. Is DOT available or not? Missing doses increase risk for relapse consider longer Rx duration What is the risk of INH resistance in the population? History of contact with drug-resistant TB case, e.g. MDR- TB, or history of failure of 1st-line treatment? Risk of drug adverse effects?

19 One explanation for the good outcomes in our study for children with HMR-TB might be that until the diagnosis was made and appropriate treatment started, they received a number of effective drugs with good CSF penetration. Using either the old or the new WHO guidelines, this would not have been the case. inha mutation = low-level INH resistant, ETH resistant katg mutation = high-level INH resistant, ETH susceptible Combination HRZEth could therefore be sufficient even if INHresistance present if given for 9 months Seddon JA, Schaaf HS, et al. PIDJ 2012;31:711

20 ETH and INH resistance in relation mutations of inha and katg genes SchaafHS, et al. EurJ MicrobiolInfect Dis 2006; 26:

21 Previously recommended TBM regimens WHO 2009: 2HRZS/4HR (or 7-10HR) adults WHO 2010: 2HRZE/10HR children AAP/ATS/IDSA 2012: 2HRZE(or Eth or S)/7-10HR) Indian Academy of Paeds 2009: 2HRZS(orE)/6-7HR SA NTP 2009: 2HRZE/4HR (but maybe for longer) SA NTP 2004: 3HRZEth/6HREth Other regimens (individual) - Ellard et al 1993: 2-3HRZS/6-9HRZ -Thwaiteset al 2004: 3HRZS/6HRZ (E for S if HIV+) -Thwaiteset al 2009: 2HRZE(S)/10HR - Donald et al 1998: 6HRZEth (children)

22 Suggested TBM regimens (Children) Drug-susceptible TBM: Strict DOT: 6HRZEth (HIV-uninfected) and 9HRZEth (HIV-infected) No DOT: 9HRZEth (most of SA) H 15mg/kg; R 20 mg/kg; Z 40 mg/kg; Eth 20 mg/kg Benefits: Covers missed doses, slow response and even INH monoresistant TB in many cases Risks: Hepatotoxicity low risk. Monitor for new-onset vomiting, abdominal pain, jaundice (late) GIT disturbance Hypothyroidism (temporary)

23 Suggested TBM regimens (Children) INH-resistant TBM Depending on mutation conferring resistance either low-level INH resistant or ethionamide resistant, therefore combination/choice RIF, PZA, Hd-INH, Eth, LFX, Tzdx 9 months Most likely overkill, but this is adding two drugs with good CSF penetration

24 Suggested TBM regimens (Children) MDR TBM Which mutation conferring INH resistance? >50% resistant to PZA and/or EMB Choice of drugs limited, outcome often poor, therefore use whatever available Hd-INH, PZA, Eth limited by possible resistance LFX (or MFX), TZD, AM, PAS, +/-LZD

25 Conclusions Most important in TBM is EARLY DIAGNOSIS TB drugs important, but also management of raised intracranial pressure and vasculitis Use effective anti-tb regimens especially look at CSF penetration of drugs Directly observed therapy and/or longer treatment duration Watch for complications of TBM and drugs

Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)

Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg

More information

TB preventive therapy in children. Introduction

TB preventive therapy in children. Introduction TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are

More information

Module 3 TREATMENT OF CHILDHOOD TB

Module 3 TREATMENT OF CHILDHOOD TB Module 3 TREATMENT OF CHILDHOOD TB Burden of TB in children Tuberculosis (TB) in children is common wherever TB is common in adults i.e. TB endemic settings TB is an important cause of illness and death

More information

Management of a child failing first line TB treatment.

Management of a child failing first line TB treatment. Management of a child failing first line TB treatment. Robert Gie Desmond Tutu Tuberculosis Centre Department of Paediatric and Child Health Stellenbosch University South Africa. Tygerberg Hospital Complex

More information

MDR, XDR, TDR-TB: Treatment and Challenges

MDR, XDR, TDR-TB: Treatment and Challenges MDR, XDR, TDR-TB: Treatment and Challenges Dr Rick Stapledon SA TB Services 2013 Australasian Tuberculosis Conference, Auckland, New Zealand Overview Introduction Historical perspective Causes of drug

More information

The Treatment of Tuberculosis

The Treatment of Tuberculosis The Treatment of Tuberculosis Treating TB Old concepts Nutritional support Fresh Air, elevation, caves Sanatoriums Weimar Exercise Surgical Death rate in 1900 was 194/100K British Sanatorium 1880s a Denver

More information

Main objectives in TB Rx

Main objectives in TB Rx Treatment of Tuberculosis in Children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Main objectives in TB Rx To rapidly kill most bacilli in order

More information

Treatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf

Treatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf Treatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg

More information

Managing Drug-Resistant Tuberculosis in Pregnancy, Mothers and Newborns. James Seddon Postgraduate Course 31 st October 2013

Managing Drug-Resistant Tuberculosis in Pregnancy, Mothers and Newborns. James Seddon Postgraduate Course 31 st October 2013 Managing Drug-Resistant Tuberculosis in Pregnancy, Mothers and Newborns James Seddon Postgraduate Course 31 st October 2013 Epidemiology WHO Global Tuberculosis Report 2012 Epidemiology Epidemiology Donald

More information

Management of Tuberculosis: Indian Guidelines

Management of Tuberculosis: Indian Guidelines Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the

More information

MDR TB. Francesca Conradie Southern African HIV Clinicians Society

MDR TB. Francesca Conradie Southern African HIV Clinicians Society MDR TB Francesca Conradie Southern African HIV Clinicians Society Disclosures Research support from the TB Alliance and Janssen TB Burden in RSA TB patients initiated on treatment decreasing: 406,082 to

More information

Module 9a NTP MANAGEMENT AND CHILD TB

Module 9a NTP MANAGEMENT AND CHILD TB Module 9a NTP MANAGEMENT AND CHILD TB Child TB and NTP What is the usual pattern of child TB cases What is impact of HIV on child TB What is important to know about treatment of TB in children Why it is

More information

I have no disclosures

I have no disclosures 1 I have no disclosures 2 3 Much of the evidence I will present in my talk is drawn from a recent systematic review and meta-analysis that I led. We assessed treatment outcome for >1600 children diagnosed

More information

MDR to XDR tuberculosis: Is evolution winning?

MDR to XDR tuberculosis: Is evolution winning? University of Michigan School of Public Health Center for Health Preparedness 2010 Symposium : Can the World be TB Free MDR to XDR tuberculosis: Is evolution winning? UTSPH Brownsville has 9 faculty and

More information

Tuberculosis. What is Tuberculosis? How is TB Contracted? What are the Symptoms?

Tuberculosis. What is Tuberculosis? How is TB Contracted? What are the Symptoms? Tuberculosis What is Tuberculosis? Tuberculosis (TB) is an infectious disease caused by a germ (bacterium). The germ is called Mycobacterium tuberculosis. This germ often affects the lungs. It may involve

More information

Chapter 6 Treatment of Tuberculosis Disease

Chapter 6 Treatment of Tuberculosis Disease Chapter 6 Treatment of Tuberculosis Disease Table of Contents Chapter Objectives.... 139 Introduction.... 141 Treatment and Monitoring Plan.... 143 Adherence Strategies... 143 TB Disease Treatment Regimens....

More information

DIAGNOSIS AND TREATMENT OF TUBERCULOSIS

DIAGNOSIS AND TREATMENT OF TUBERCULOSIS DIAGNOSIS AND TREATMENT OF TUBERCULOSIS James Sunstrum, M.D. Beaumont Health 2014 MFMER slide-1 Disclosure and Objectives Disclosure: No conflicts of interest =============================== Objectives

More information

Matthew D. Whitson, RN has the following disclosures to make:

Matthew D. Whitson, RN has the following disclosures to make: Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Are we there yet?: Completion of treatment and dose counting Presented by Matthew D. Whitson, RN February 25, 2015 Matthew

More information

New Anti-Tuberculosis Drugs

New Anti-Tuberculosis Drugs New Anti-Tuberculosis Drugs Dr.Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services. Classification of Drug Resistant Tuberculosis Primary

More information

Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015

Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme

More information

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section

More information

Treatment of TB: An Overview

Treatment of TB: An Overview Treatment of TB: An Overview Pennsylvania TB Update - 2011 August 5, 2011 Lee B. Reichman, MD, MPH History of Treatment of Latent Tuberculosis Infection Targeted Tuberculin Testing and Treatment of Latent

More information

Drug Resistant TB A Clinician s Perpsective

Drug Resistant TB A Clinician s Perpsective Drug Resistant TB A Clinician s Perpsective Associate Professor Paul Willcox Respiratory Clinic, Groote Schuur Hospital, University of Cape Town Lung Institute and University of Cape Town Private Academic

More information

Tuberculosis in Pregnancy

Tuberculosis in Pregnancy Tuberculosis in Pregnant versus non- Tuberculosis in Pregnancy Mark J. Granada, MD Means of Spreading TB bacilli Coughing Sneezing Singing Spitting Laughing Rarely, pregnant TB patient may pass TB to unborn

More information

Self-Study Modules on Tuberculosis

Self-Study Modules on Tuberculosis Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National

More information

TUBERCULOSIS (TB) Jotam G. Pasipanodya Gumbo lab

TUBERCULOSIS (TB) Jotam G. Pasipanodya Gumbo lab TUBERCULOSIS (TB) Jotam G. Pasipanodya Gumbo lab History of TB History of TB Historically known by a variety of names, including: Consumption Wasting disease White plague Sanatorium was part of treatment

More information

MANAGEMENT of TB. James Sunstrum, M.D. Michigan Dept. of Community Health MFMER slide-1

MANAGEMENT of TB. James Sunstrum, M.D. Michigan Dept. of Community Health MFMER slide-1 MANAGEMENT of TB James Sunstrum, M.D. Michigan Dept. of Community Health 2014 MFMER slide-1 Disclosures Relevant Financial Relationships: none ========================= Off label discussions of rifapentine

More information

Draft minutes Workshop on formulation of guidelines for diagnosis and treatment of Pediatric TB cases under RNTCP 6-7 th August 2003, New Delhi

Draft minutes Workshop on formulation of guidelines for diagnosis and treatment of Pediatric TB cases under RNTCP 6-7 th August 2003, New Delhi Draft minutes Workshop on formulation of guidelines for diagnosis and treatment of Pediatric TB cases under RNTCP 6-7 th August 2003, New Delhi Objectives of the meeting: To arrive at consensus on the

More information

DRUG RESISTANT TUBERCULOSIS guideline based approach. Dr. v.laxmanbabu MD Assist.professor

DRUG RESISTANT TUBERCULOSIS guideline based approach. Dr. v.laxmanbabu MD Assist.professor DRUG RESISTANT TUBERCULOSIS guideline based approach Dr. v.laxmanbabu MD Assist.professor OBJECTIVES To Familiarise the students with Current scenario of drug resistance in tuberculosis. Types of drug

More information

Recent Advances in The Treatment of Mycobacterium Tuberculosis

Recent Advances in The Treatment of Mycobacterium Tuberculosis Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my

More information

Recognised as a world leader and a prominent clinical researcher in South Africa

Recognised as a world leader and a prominent clinical researcher in South Africa Expert Talks Prof. Peter Donald Emeritus professor in Pediatrics and Child Health at the Faculty of Health Sciences of the University of Stellenbosch and Tygerberg Children's Hospital, South frica n internationally

More information

X-Plain Pediatric Tuberculosis Reference Summary

X-Plain Pediatric Tuberculosis Reference Summary X-Plain Pediatric Tuberculosis Reference Summary Introduction Tuberculosis, or TB, is a bacterial infection that causes more deaths in the world than any other infectious disease. When a child gets TB,

More information

A REVIEW ON THE TREATMENT OF TB, MDR TB, XDR TB AND TDR TB

A REVIEW ON THE TREATMENT OF TB, MDR TB, XDR TB AND TDR TB 35 Khade A. A. et al IJPPR.HUMAN, 2014; Vol. 1(1): 35-40. (Review Article) A REVIEW ON THE TREATMENT OF TB, MDR TB, XDR TB AND TDR TB Akash Balwant, Abhijeet Barde, Amitkumar Anandrao Khade Government

More information

HIV & TUBERCULOSIS TREATMENT, PREVENTION AND CONTROL

HIV & TUBERCULOSIS TREATMENT, PREVENTION AND CONTROL HIV & TUBERCULOSIS TREATMENT, PREVENTION AND CONTROL Important differences in Treatment of patients with TB when coinfected with HIV Treatment of TB in presence of HIV infection is essentially the same

More information

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die

More information

Drug Resistant Tuberculosis

Drug Resistant Tuberculosis Drug Resistant Tuberculosis Michael Lauzardo, MD MSc Director, Southeastern National Tuberculosis Center Chief, Division of Infectious Diseases and Global Medicine University of Florida Section 1

More information

Treatment of TB Disease

Treatment of TB Disease Treatment of TB Disease The Basics Jennifer Whitaker, MD, MS Tuberculosis Clinical Intensive Program, Mayo Clinic, Rochester November 19, 2013 2013 MFMER slide-1 Disclosures Pfizer Educational Grant for

More information

Tuberculosis in renal and liver disease

Tuberculosis in renal and liver disease Tuberculosis in renal and liver disease Dr Evan Shoul Wits University, Division of Infectious Diseases Southern African HIV Clinicians Society Conference April 2016 Mr HL 56 year old man from Alex Main

More information

Tuberculous meningitis

Tuberculous meningitis Tuberculous meningitis Digital Pathology Collection Case 12 2011 Ref. RCCH170 RXH PM243/86 Clinical Data This 31 month child was admitted to a country hospital following a seizure. She became unconscious

More information

Summary of the risk management plan (RMP) for Sirturo (bedaquiline)

Summary of the risk management plan (RMP) for Sirturo (bedaquiline) EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure

More information

Treatment. Introduction... 32. Individualized Regimens.. 33. Selection and Dosing of Drugs... 41. Administration of the Regimen...

Treatment. Introduction... 32. Individualized Regimens.. 33. Selection and Dosing of Drugs... 41. Administration of the Regimen... Treatment 3 Introduction............ 32 Individualized Regimens.. 33 Monoresistance......... 33 Polyresistance.......... 34 Multidrug Resistance..... 35 Extensive Drug Resistance 39 Selection and Dosing

More information

TB & HIV co infection interactions, considerations, pitfalls. Dr Sindisiwe van Zyl

TB & HIV co infection interactions, considerations, pitfalls. Dr Sindisiwe van Zyl TB & HIV co infection interactions, considerations, pitfalls Dr Sindisiwe van Zyl Background facing a double epidemic TB leads to HIV disease progression & vice versa 70% TB patients are HIV co infected

More information

Managing LFT abnormalities in TB HIV patients. Dr TC Manzini Department of Infectious Diseases UKZN/KEH

Managing LFT abnormalities in TB HIV patients. Dr TC Manzini Department of Infectious Diseases UKZN/KEH Managing LFT abnormalities in TB HIV patients Dr TC Manzini Department of Infectious Diseases UKZN/KEH Introduction DILI in TB/HIV co-infected patients is a common problem in the SA setting Re-introduction

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical Intensive Oakland Treatment of Tuberculosis September 30, 2015 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author HIV-positive patients with tuberculosis - epidemiology, best timing of starting antiretroviral therapy and management of IRIS-TB Ole Kirk, Copenhagen, Denmark 23 rd European Congress of Clinical Microbiology

More information

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,

More information

MANAGEMENT OF TUBERCULOSIS

MANAGEMENT OF TUBERCULOSIS MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION

More information

PEDIATRIC TUBERCULOSIS. Hot topics / Unresolved issues in Clinical Practice

PEDIATRIC TUBERCULOSIS. Hot topics / Unresolved issues in Clinical Practice PEDIATRIC TUBERCULOSIS Hot topics / Unresolved issues in Clinical Practice Ann M. Loeffler, M.D. Legacy Emanuel Children s Hospital Portland, OR Faculty Consultant Francis J. Curry National TB Center February

More information

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in

More information

LEARNING OUTCOMES. Identify children at risk of developing TB disease. Correctly manage and refer children suspected of TB. Manage child contacts

LEARNING OUTCOMES. Identify children at risk of developing TB disease. Correctly manage and refer children suspected of TB. Manage child contacts TB in Children 1a TB IN CHILDREN 2 LEARNING OUTCOMES Identify children at risk of developing TB disease Correctly manage and refer children suspected of TB Manage child contacts 3 TB Infection and Disease

More information

Isoniazid preventive therapy for children: impact on mortality and incidence of tuberculosis?

Isoniazid preventive therapy for children: impact on mortality and incidence of tuberculosis? Isoniazid preventive therapy for children: impact on mortality and incidence of tuberculosis? Charles D. Mitchell, University if Miami Miller School of Medicine HIV/TB Research Meeting March 3, 2013 Adults

More information

Tuberculosis in Children and Adolescents

Tuberculosis in Children and Adolescents Tuberculosis in Children and Adolescents Ritu Banerjee, MD, Ph.D TB Clinical Intensive April 8, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Describe the epidemiology of pediatric

More information

Tuberculosis Pharmacy Reporting

Tuberculosis Pharmacy Reporting Tuberculosis Pharmacy Reporting Christina M. Madison, Pharm.D., BCACP Assistant Professor of Pharmacy Practice Roseman University of Health Sciences Clinical Pharmacy Faculty Southern Nevada Health District

More information

Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment

Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Tuberculosis Airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tb) M. tb complex (MTBC) includes

More information

Approach to managing the child exposed to tuberculosis

Approach to managing the child exposed to tuberculosis Approach to managing the child exposed to tuberculosis James Nuttall Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital & University of Cape Town GP Paediatric Update, 5+6 October

More information

Doing the Math: The Dilemma of Drug Resistant Tuberculosis. Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012

Doing the Math: The Dilemma of Drug Resistant Tuberculosis. Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012 Doing the Math: The Dilemma of Drug Resistant Tuberculosis Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012 Tuberculosis : A Global Problem WHO Estimates (2010 data): 8.8 million New Infections

More information

Guideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0

Guideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0 Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother

More information

Treatment of Drug Resistant TB

Treatment of Drug Resistant TB Objectives Treatment of Drug Resistant TB Diana M. Nilsen, RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Definition of other drug resistant (ODR), multiple drug resistant

More information

Treatment of childhood tuberculosis

Treatment of childhood tuberculosis Treatment of childhood tuberculosis Iveta Ozere The State Agency of Tuberculosis and Lung Diseases, Latvia IUATLD Euro Region Conference Dubrovnik, Croatia, 27-30 May 2009 Numbers of newly diagnosed TB

More information

Extensively drug-resistant TB in Eastern Cape: High Mortality in HIV-negative and patients

Extensively drug-resistant TB in Eastern Cape: High Mortality in HIV-negative and patients TB Epidemiology and Intervention Research Unit Extensively drug-resistant TB in Eastern Cape: High Mortality in HIV-negative and HIV-positive patients TB Epidemiology and Inter rvention Research Unit Charlotte

More information

Chapter Four: Treatment of Tuberculosis Disease

Chapter Four: Treatment of Tuberculosis Disease Chapter Four: Treatment of Tuberculosis Disease The standard of tuberculosis (TB) treatment in Los Angeles County (LAC) is to initiate an appropriate chemotherapeutic regimen along with Directly Observed

More information

Tuberculosis and Early Case Finding

Tuberculosis and Early Case Finding TUBIDU III International Training in Bucharest, Romania 27th 28th of February2014 Tuberculosis and Early Case Finding Piloting of TUBIDU Handbook Abbrevationsand acronyms TB Tuberculosis MDR-TB Multi drug-resistant

More information

Tuberculosis: prevention, diagnosis, management and service organisation

Tuberculosis: prevention, diagnosis, management and service organisation Tuberculosis: prevention, diagnosis, management and service organisation Review questions Number A B C D E F G H I J Review question What are the most effective methods for i) sputum smear microscopy and

More information

Managing TB with Preexisting. Disease

Managing TB with Preexisting. Disease Managing TB with Preexisting Liver and Kidney Disease Alfred Lardizabal, MD Global Tuberculosis Institute at UMDNJ 68 y/o male Samoan with end stage renal disease Multiple medical problems including CHF

More information

TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES

TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES ALWAYS USE AT LEAST 2 DRUGS: Begin with 4 pending sensitivities Natural incidence of spontaneous resistance to any 1 drug= 1

More information

Tuberculosis Treatment: Drug Therapy, Case Management, & Special Considerations

Tuberculosis Treatment: Drug Therapy, Case Management, & Special Considerations Tuberculosis Treatment: Drug Therapy, Case Management, & Special Considerations Take Home Information for Attendees of the 2014 Intergovernmental Panel Physicians Training Summit Principles of Tuberculosis

More information

TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS

TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS Policy brief, March 2015 Tuberculosis (TB), a communicable disease that affects 9 million people worldwide,

More information

MDR TB XDR TB The Laboratory - A Clinician s Perspective

MDR TB XDR TB The Laboratory - A Clinician s Perspective MDR TB XDR TB The Laboratory - A Clinician s Perspective Barbara J Seaworth M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director Heartland National TB Center Partnership

More information

IMPAACT P1101 STUDY TRAINING

IMPAACT P1101 STUDY TRAINING IMPAACT P1101 STUDY TRAINING VERSION 2.0, 19 JUNE 2015 TAMMY MEYERS, MD, PROTOCOL CO-CHAIR PAUL KROGSTAD, MD, PROTOCOL CO-CHAIR DECEMBER 2015 2 IMPAACT P1101 ELIGIBILITY CRITERIA INCLUSION CRITERIA 4.1.1

More information

Objectives. Outline. Epidemiology, Treatment and Prevention of MDR-TB. C. Robert Horsburgh, Jr. Boston University School of Public Health

Objectives. Outline. Epidemiology, Treatment and Prevention of MDR-TB. C. Robert Horsburgh, Jr. Boston University School of Public Health Objectives Epidemiology, Treatment and Prevention of MDR-TB C. Robert Horsburgh, Jr. Boston University School of Public Health To document the extent of the global MDR-TB epidemic and suggest where it

More information

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27 TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be

More information

Minnesota Department of Health Tuberculosis Prevention and Control Program (651) Tuberculosis surveillance data for Minnesota are available

Minnesota Department of Health Tuberculosis Prevention and Control Program (651) Tuberculosis surveillance data for Minnesota are available Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available on the Web at: www.health.state.mn.us/tb Year No. Cases

More information

Guidelines for the management of tuberculosis in children living in San Diego County 2003

Guidelines for the management of tuberculosis in children living in San Diego County 2003 Guidelines for the management of tuberculosis in children living in San Diego County 2003 San Diego Pediatric TB Task Force Subcommittee on guidelines for the management of pediatric tuberculosis Alice

More information

INCIDENCE AND RISK FACTORS FOR HEPATITIS IN PATIENTS RECEIVING ANTITUBERCULAR TREATMENT

INCIDENCE AND RISK FACTORS FOR HEPATITIS IN PATIENTS RECEIVING ANTITUBERCULAR TREATMENT INCIDENCE AND RISK FACTORS FOR HEPATITIS IN PATIENTS RECEIVING ANTITUBERCULAR TREATMENT Manish Kumar Singh, Mamatha. S, Rashee Jain, Amit Kumar Jha, Sanjay Kumar Nigam 1. Assistant Professor, Department

More information

Case Discussions: Managing Toxicities of Anti TB Medications

Case Discussions: Managing Toxicities of Anti TB Medications Case Discussions: Managing Toxicities of Anti TB Medications Henry Fraimow, MD Division of Infectious Diseases, Cooper University Hospital, Camden, NJ Medical Consultant, Southern New Jersey Regional Chest

More information

Beyond XDR TB. Case Presentation. Past Medical History. Caitlin Reed 2014 National TB Conference Atlanta, Georgia June 12, 2014

Beyond XDR TB. Case Presentation. Past Medical History. Caitlin Reed 2014 National TB Conference Atlanta, Georgia June 12, 2014 Beyond XDR TB Caitlin Reed MD, MPH Medical Director, Inpatient TB Unit Assistant Professor, Division of Infectious Diseases Olive View UCLA Medical Center Los Angeles County Department of Health Services

More information

TB Case Management. Adriene Rister, TB Control Coordinator Mainely TB Conference April 14, 2011

TB Case Management. Adriene Rister, TB Control Coordinator Mainely TB Conference April 14, 2011 TB Case Management Adriene Rister, TB Control Coordinator Mainely TB Conference April 14, 2011 Objectives Define case management and the goals of TB case management Review how to apply the nursing process

More information

Tuberculosis in Mauritius. Dr R RPurryag Chest Physician Chest Clinic

Tuberculosis in Mauritius. Dr R RPurryag Chest Physician Chest Clinic Tuberculosis in Mauritius Dr R RPurryag Chest Physician Chest Clinic Robert Koch (1843 1910) and Nobel Prize in Physiology and Medicine in 1905 2 .yet Worldwide in 2014 9.6 million people were estimated

More information

THE GOVERNMENT OF THE KINGDOM OF SWAZILAND MINISTRY OF HEALTH AND SOCIAL WELFARE P. O. BOX 5 MBABANE

THE GOVERNMENT OF THE KINGDOM OF SWAZILAND MINISTRY OF HEALTH AND SOCIAL WELFARE P. O. BOX 5 MBABANE THE GOVERNMENT OF THE KINGDOM OF SWAZILAND MINISTRY OF HEALTH AND SOCIAL WELFARE P. O. BOX 5 MBABANE DRUG RESISTANT TUBERCULOSIS MANAGEMENT GUIDELINES AND MANUAL NOVEMBER 2008 1 FOREWORD Swaziland has

More information

MDR/ XDR TB KZN Update. Dr I H Master King George V Hospital Department of Health (KZN) 06/10/2011

MDR/ XDR TB KZN Update. Dr I H Master King George V Hospital Department of Health (KZN) 06/10/2011 MDR/ XDR TB KZN Update Dr I H Master King George V Hospital Department of Health (KZN) 06/10/2011 SA Estimates of burden Reported to WHO - 2009 Enrolled MDR Cases 2009 9600 MDR in New TB 5200 MDR in

More information

ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES

ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed

More information

Overview of Tuberculosis (TB)

Overview of Tuberculosis (TB) Overview of Tuberculosis (TB) 1. Overview of Tuberculosis 1.1 Introduction Welcome to the Association of Public Health Laboratories essentials for the Microbacteriology Laboratory promoting quality Practices.

More information

DRUG RESISTANT TUBERCULOSIS: AN HISTORICAL OVERVIEW

DRUG RESISTANT TUBERCULOSIS: AN HISTORICAL OVERVIEW DRUG RESISTANT TUBERCULOSIS: AN HISTORICAL OVERVIEW SALMAAN KESHAVJEE MD, PhD, ScM JULY 10, 2012 https://drtbnetwork.org/ DRUG-RESISTANT TUBERCULOSIS: AN HISTORICAL OVERVIEW SALMAAN KESHAVJEE, MD, PhD,

More information

Pregnancy and Tuberculosis. Information for clinicians

Pregnancy and Tuberculosis. Information for clinicians Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB

More information

Standardised regimen for adult XDR-TB treatment

Standardised regimen for adult XDR-TB treatment Standardised regimen for adult XDR-TB treatment Injectable Phase: Treatment taken daily for at least 6 months Patient weight Drug Dosage < 33 kg 33 50 kg 51 70 kg > 70 kg Capreomycin Capreomycin Capreomycin

More information

MDR-/XDR-TB management: what it was, current standards and what is ahead

MDR-/XDR-TB management: what it was, current standards and what is ahead MDR-/XDR-TB management: what it was, current standards and what is ahead Expert Rev. Resp. Med. 3(2), 133 145 (2009) Ignacio Monedero and Jose A Caminero Author for correspondence Servicio de Neumología,

More information

DOTS-Plus & Green Light Committee

DOTS-Plus & Green Light Committee DOTS-Plus & Green Light Committee the Improving access to second-line anti-tb drugs World Health Organization WHO/CDS/TB/2000.283 Distribution: General Original: English Current global tuberculosis (TB)

More information

Emerging Infectious Disease (4): Drug-Resistant Tuberculosis

Emerging Infectious Disease (4): Drug-Resistant Tuberculosis S67 Drug-Resistant Tuberculosis Emerging Infectious Disease (4): Drug-Resistant Tuberculosis Chi-Fang You, MD; Han-Ping Ma, MD; Tzong-Luen Wang, MD, PhD; Aming Chor-Min Lin, MD Abstract Before the discovery

More information

TB Treatment: To Cure and Protect

TB Treatment: To Cure and Protect TB Treatment: To Cure and Protect Session Three of a Four-Part Webinar Series Presented in Partnership with the BC Lung Association Facilitators: Nash Dhalla, Program Coordinator & Nurse Consultant, TB

More information

MDR-TB Diagnosis and Management

MDR-TB Diagnosis and Management MDR-TB Diagnosis and Management Definition MDR-TB caused by strains of Mycobacterium Tuberculosis resistant both Rifampicin and Isoniazid with or without resistance to other drugs. Single Isoniazid or

More information

Module 5 CHILD TB/HIV

Module 5 CHILD TB/HIV Module 5 CHILD TB/HIV The challenge of HIV and TB/HIV Increased caseload of child TB Greater difficulty with diagnosis Poorer response to TB treatment Drug interactions Implementation of the three I s

More information

2011 NTP Paediatric guidelines update- final draft

2011 NTP Paediatric guidelines update- final draft Childhood TB Investigation and management of children suspected to have tuberculosis (TB) or who are close contacts of a TB case (sputum smear positive or negative) Key facts Children who are close contacts

More information

Médecins Sans Frontières Khayelitsha

Médecins Sans Frontières Khayelitsha Médecins Sans Frontières Khayelitsha Decentralized diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa Outcomes and successes of the decentralized model of care March 2015

More information

TB Drug Pipeline and New Treatment Combinations for MDR-TB. C. Robert Horsburgh, Jr., MD Boston University School of Public Health, Boston, MA USA

TB Drug Pipeline and New Treatment Combinations for MDR-TB. C. Robert Horsburgh, Jr., MD Boston University School of Public Health, Boston, MA USA TB Drug Pipeline and New Treatment Combinations for MDR-TB C. Robert Horsburgh, Jr., MD Boston University School of Public Health, Boston, MA USA Outline Background Repurposable drugs for MDR-TB New drugs

More information

Gaps in the diagnosis and management of severe TB in children Red Flags

Gaps in the diagnosis and management of severe TB in children Red Flags This presentation is provided on the South African Child Health Priorities Website as presented at the 5 th Child Health Priorities Conference except that potential patient identifying content has been

More information

12 Points of Tuberculosis (TB) Patient Education

12 Points of Tuberculosis (TB) Patient Education 12 Points of Tuberculosis (TB) Patient Education Transmission of TB TB is a disease caused by the TB germ. The disease is mainly in the lungs (pulmonary TB), but the germ can travel to other parts of the

More information

Management of Side Effects during MDR-TB Treatment

Management of Side Effects during MDR-TB Treatment Management of Side Effects during MDR-TB Treatment Serena Koenig, MD, MPH Partners In Health Division of Global Health Equity Division of Infectious Disease Brigham and Women s Hospital Side Effects Patients

More information

NEW JERSEY TUBERCULOSIS CASE, SUSPECT AND STATUS REPORT SHADED AREAS ARE FOR STATE USE ONLY; LEAVE BLANK.

NEW JERSEY TUBERCULOSIS CASE, SUSPECT AND STATUS REPORT SHADED AREAS ARE FOR STATE USE ONLY; LEAVE BLANK. SHADED AREAS ARE FOR STATE USE ONLY; LEAVE BLANK. Type of Report: Initial Recurrence Current Status Patient s Name (Last, First, MI) 4. Street Address: (Check if New ) Within City Limits: Yes No County:

More information